报道了反式-(+-)-N-甲基-2-(3-吡啶基)-2-四氢硫代吡喃氨基甲磺酰胺+++ e 1-氧化物(8a,RP 49356)和类似物的合成和生物活性。这些化合物构成K(+)通道开放剂的新结构类。讨论了吡啶基,硫代酰胺和硫杂环上的变化对体外K(+)通道开放反应性的影响。为了活性,优选3-吡啶基或3-喹啉基,小的N-烷基硫代酰胺官能团和氧化亚砜环,其中亚砜与硫代酰胺具有反式关系。选择的化合物在降压麻醉的大鼠中静脉内测试降压作用,其活性反映了其体外K(+)通道的开放活性。
报道了反式-(+-)-N-甲基-2-(3-吡啶基)-2-四氢硫代吡喃氨基甲磺酰胺+++ e 1-氧化物(8a,RP 49356)和类似物的合成和生物活性。这些化合物构成K(+)通道开放剂的新结构类。讨论了吡啶基,硫代酰胺和硫杂环上的变化对体外K(+)通道开放反应性的影响。为了活性,优选3-吡啶基或3-喹啉基,小的N-烷基硫代酰胺官能团和氧化亚砜环,其中亚砜与硫代酰胺具有反式关系。选择的化合物在降压麻醉的大鼠中静脉内测试降压作用,其活性反映了其体外K(+)通道的开放活性。
General and cost-effective synthesis of 1-heteroaryl/arylcycloalkylamines and their broad applications
作者:Dehui Zhang、Hongchao Zheng、Xiaodong Wang
DOI:10.1016/j.tet.2016.02.060
日期:2016.4
A general and cost-effectiveroute has been developed to synthesize 1-heteroarylsubstituted cycloalkylamines from readily available heteroarylacetate in good yields. This synthesis features a LHMDS promoted cyclization and one-pot hydrolysis/Curtius rearrangement. This route can be easily carried out on multi-gram scale and be also used to prepare 1-arylsubstituted cycloalkyl/cycloheteroalkylamines
[EN] COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS<br/>[FR] COMPLEXES DE CUIVRE DESTINÉS AU TRAITEMENT D'ÉTATS NEURODÉGÉNÉRATIFS
申请人:ALS THERAPY DEVELOPMENT INST
公开号:WO2022047014A1
公开(公告)日:2022-03-03
The present disclosure relates to copper complexes, pharmaceutical compositions comprising these complexes, chemical processes for preparing these complexes, and their use in the treatment of neurodegenerative disease, e.g., amyotrophic lateral sclerosis (ALS).
N-(Arylacetyl)-biphenylalanines as Potent VLA-4 Antagonists
作者:Bing Li、Stephen E de Laszlo、Theodore M Kamenecka、Ihor E Kopka、Philippe L Durette、Thomas Lanza, Jr、Malcolm MacCoss、Sharon Tong、Richard A Mumford、Ermengilda D McCauley、Gail Van Riper、John A Schmidt、William K Hagmann
DOI:10.1016/s0960-894x(02)00366-9
日期:2002.8
A series of potent N-(aralkyl-, arylcycloalkyl-, and heteroaryl-acyl)-4-biphenylalanine VLA-4 antagonists was prepared by rapid analogue methods using solid-phase chemistry. Further optimization led to several highly potent compounds (IC50 < 1 nM). Evaluation of rat pharmacokinetic revealed generally high clearance. (C) 2002 Elsevier Science Ltd. All rights reserved.
HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND PHARMACEUTICAL USE